ALK and lung cancer: Western blot analysis (Fig. 4) showed a gradual decrease in pALK and pERK expression upon 30, 100, 300 nM crizotinib on the EML-ALK v3 harboring JVE404 cells (pALK +2, −8, −49%, respectively, and pERK −35, −63, −68%, respectively), but less pronounced than on NCI-H2228 (lung cancer cell line, also characterized by EML4-ALK v3) (pALK −35, −59, −80%, respectively, and pERK −58, −89, −96%, respectively) (also see Supplementary Figs 3 and 4).